NCT05600127View on ClinicalTrials.gov

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2026

Conditions
Urothelial Carcinoma
Interventions
DRUG

Avelumab

3 cycles of avelumab (800mg, every 2 weeks)

Trial Locations (4)

6525 GD

RECRUITING

Radboud UMC, Nijmegen

5223 GZ

RECRUITING

Jeroen Bosch ziekenhuis, 's-Hertogenbosch

4818 CK

RECRUITING

Amphia ziekenhuis, Breda

3015 GD

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Erasmus Medical Center

OTHER